IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality.

J Crohns Colitis · 2022 · PMC9097672 · PMID 35553662

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The result for the primary endpoint of clinical remission at week 12 for the mirikizumab 600-mg group did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.